Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798982 | PMC |
| http://dx.doi.org/10.21037/tcr.2019.02.10 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk prediction of advanced colorectal neoplasia varies by race and neighbourhood socioeconomic status.
Fam Med Community Health
May 2024
Department of Family Medicine, University of Virginia, Charlottesville, Virginia, USA
Objective: Neighbourhood deprivation increases the risk of colorectal neoplasia and contributes to racial disparities observed in this disease. Developing race-specific advanced colorectal neoplasia (ACN) prediction models that include neighbourhood socioeconomic status has the potential to improve the accuracy of prediction.
Methods: The study includes 1457 European Americans (EAs) and 936 African Americans (AAs) aged 50-80 years undergoing screening colonoscopy.
Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder.
JAMA Netw Open
September 2024
Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO).
J Natl Cancer Inst
January 2025
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.
Article Synopsis
- Chemotherapy often leads to side effects that can negatively affect treatment outcomes, while exercise during treatment has shown benefits for physical functioning and mental health, but its impact on clinical outcomes like chemotherapy dose intensity is uncertain.
- The ENICTO Consortium, funded by the National Cancer Institute, aims to fill this knowledge gap by exploring how exercise and nutrition may improve chemotherapy-related outcomes and detailing distinct research projects within their framework.
- The findings from ENICTO could change oncology care practices, making exercise and nutrition support a standard part of cancer treatment alongside chemotherapy to enhance overall effectiveness and patient outcomes.
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
Ann Intern Med
August 2024
Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio (R.X.).
Background: Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs).
Objective: To examine the association of semaglutide with TUD-related health care measures in patients with comorbid T2DM and TUD.
Design: Emulation target trial based on a nationwide population-based database of patient electronic health records.
Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study.
Cancers (Basel)
June 2024
Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Lung cancer (LC) is the second most common cancer and the leading cause of cancer deaths in the U.S. Insulin therapy, a key treatment for managing Type 2 Diabetes Mellitus (T2DM), is associated with increased LC risk.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!